Skip to Content

'
Junya Fujimoto, M.D., Ph.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Coordinator, UT-Lung SPORE Tissue Bank, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 0951
Houston, TX 77030
Room Number: B6.4620
Phone: 713-745-4314
Fax: 713-563-8821
Email: jfujimot@mdanderson.org

Education & Training

Degree-Granting Education

2000 Hiroshima University Graduate School of Medicine, Hiroshima, Hiroshima, Japan, PHD, Pathology
1996 Hiroshima University School of Medicine, Hiroshima, Hiroshima, Japan, MD, Medicine

Postgraduate Training

4/2004-3/2009 Research Fellowship, Pathology, Molecular Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, Dr. Reuben Lotan
4/2001-3/2004 Clinical Fellowship, Surgical Pathology, National Kure Medical Center / Chugoku Cancer Center, Kure, Hiroshima, Japan
4/2000-7/2000 Clinical Residency, Hiroshima University Hospital, Hiroshima, Hiroshima, Japan, Dr. Wataru Yasui

Board Certifications

4/2011 Academic Councilor, Japanese Society of Pathology
7/2003 Pathology, Japanese Board of Pathology

Experience/Service

Academic Appointments

Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 11/2012-7/2013
Instructor, Department of Thoracic/Head and Neck Medical Oncology - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2009-10/2012
Assistant Professor, First Department of Pathology, Hiroshima Univesity School of Medicine, Hiroshima, Hiroshima, Japan, 8/2000-3/2001

Honors and Awards

2007 AACR-AstraZeneca Scholar-in-Training Awards 2007, The American Association for Cancer Research

Professional Memberships

American Association for Cancer Research, Philadelphia, PA
Active Member, 4/2009-present
American Society of Clinical Pathology
International BOR certified Member, 2007-present
International Society of Differentiation, Inc.
Member, 1998-present
International Society of Gastroenterological Carcinogenesis, Japan
Member, 1997-present
Japanese Cancer Association, Japan
Member, 1997-present
Japanese Society of Pathology, Japan
Member, 1997-present
Pulmonary Pathology Society
Member, 7/2011-present
The United States & Canadian Academy of Pathology, Augusta, GA
Member, 10/2010-present
West Japan Oncology Group, Japan
Member, 11/2011-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Zhang J, Fujimoto J, Zhang J, Wedge DC, Song X, Zhang J, Seth S, Chow CW, Cao Y, Gumbs C, Gold KA, Kalhor N, Little L, Mahadeshwar H, Moran C, Protopopov A, Sun H, Tang J, Wu X, Ye Y, William WN, Lee JJ, Heymach JV, Hong WK, Swisher S, Wistuba II, Futreal PA. Intra-tumor Heterogeneity in Localized Lung Adenocarcinomas Delineated by Multi-region Sequencing. Science 346(6206):256-9, 10/10/2014. PMID: 25301631.
2. Augustyn A, Borromeo M, Wang T, Fujimoto J, Shao C, Dospoy PD, Lee V, Tan C, Sullivan JP, Larsen JE, Girard L, Behrens C, Wistuba II, Xie Y, Cobb MH, Gazdar AF, Johnson JE, Minna JD. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers. Proc Natl Acad Sci U S A. e-Pub 9/29/2014. PMID: 25267614.
3. Weissferdt A, Kalhor N, Liu H, Rodriguez J, Fujimoto J, Tang X, Wistuba II, Moran CA. Thymic neuroendocrine tumors (paraganglioma and carcinoid tumors): a comparative immunohistochemical study of 46 cases. Hum Pathol. e-Pub 9/6/2014. PMID: 25294372.
4. Kim ES, Tang X, Peterson DR, Kilari D, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Stewart DJ, Wistuba II, Siddik ZH. Copper Transporter CTR1 Expression and Tissue Platinum Concentration in Non-Small Cell Lung Cancer. Lung Cancer 85(1):88-93, 7/2014. e-Pub 4/22/2014. PMCID: PMC4090351.
5. Tsao AS, Harun N, Fujimoto J, Devito V, Lee JJ, Kuhn E, Mehran R, Rice D, Moran C, Hong WK, Shen L, Suraokar M, Wistuba I. Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. Ann Diagn Pathol 18(3):140-145, 6/2014. e-Pub 2/20/2014. PMCID: PMC4136493.
6. Kadara H, Fujimoto J, Yoo SY, Maki Y, Gower AC, Kabbout M, Garcia MM, Chow CW, Chu Z, Mendoza G, Shen L, Kalhor N, Hong WK, Moran C, Wang J, Spira A, Coombes KR, Wistuba II. Transcriptomic architecture of the adjacent airway field cancerization in nonsmall cell lung cancer. J Natl Cancer Inst 106(3):dju004, 3/2014. e-Pub 2/22/2014. PMCID: PMC3982778.
7. Wistuba II, Behrens C, Lombardi F, Wagner S, Fujimoto J, Raso MG, Spaggiari L, Galetta D, Riley R, Hughes E, Reid J, Sangale Z, Swisher SG, Kalhor N, Moran CA, Gutin A, Lanchbury JS, Barberis M, Kim ES. Validation of a Proliferation-based Expression Signature as Prognostic Marker in Early Stage Lung Adenocarcinoma. Clin Cancer Res 19(22):6261-6271, 11/15/2013. e-Pub 9/18/2013. PMCID: PMC3834029.
8. Liu H, Tang X, Fujimoto J, Rodriguez J. Laser Capture Microdissection for the Investigative Pathologist. Veterinary Pathology. e-Pub 11/2013. PMID: 24227008.
9. Kabbout M, Garcia MM, Fujimoto J, Liu DD, Woods D, Chow CW, Mendoza G, Momin AA, James BP, Solis L, Behrens C, Lee JJ, Wistuba II, Kadara H. ETS2 mediated tumor suppressive function and MET oncogene inhibition in human non-small cell lung cancer. Clin Cancer Res 19(13):3383-3395, 7/1/2013. e-Pub 5/9/2013. PMCID: PMC3846434.
10. Yang Z, Guan B, Men T, Fujimoto J, Xu X. Comparable molecular alterations in 4-nitroquinoline 1-ooxide induced oral and esophageal cancer in mice and in human esophageal cancer, associated with poor prognosis of patients. In Vivo 27(4):473-484, Jul-Aug, 7/2013. PMCID: PMC3849809.
11. Kadara H, Shen L, Fujimoto J, Saintigny P, Chow CW, Lang W, Chu Z, Garcia M, Kabbout M, Fan YH, Behrens C, Liu DA, Mao L, Lee JJ, Gold KA, Wang J, Coombes KR, Kim ES, Hong WK, Wistuba II. Characterizing the molecular spatial and temporal field of injury in early stage smoker non-small cell lung cancer patients after definitive surgery by expression profiling. Cancer Prev Res (Phila) 6(1):8-17, 1/2013. e-Pub 10/19/2012. PMCID: PMC3774536.
12. Fujimoto J, Kadara H, Garcia MM, Kabbout M, Behrens C, Liu DD, Lee JJ, Solis LM, Kim ES, Kalhor N, Moran C, Sharafkhaneh A, Lotan R, Wistuba II. G-protein coupled receptor family C group 5 member A (GPRC5A) expression is decreased in the adjacent field and normal bronchial epithelia of patients with chronic obstructive pulmonary disease and non-small cell lung cancer. J Thorac Oncol 7(12):1747-54, 12/2012. PMCID: PMC3622592.
13. Kim ES, Lee JJ, He G, Chow CW, Fujimoto J, Kalhor N, Swisher SG, Wistuba II, Stewart DJ, Siddik ZH. Tissue Platinum Concentration and Tumor Response in Non-small Cell Lung Cancer. J Clin Oncol 30(27):3345-52, 9/20/2012. e-Pub 8/13/2012. PMCID: PMC3438232.
14. Weissferdt A, Lin H, Woods D, Tang X, Fujimoto J, Wistuba II, Moran CA. HER family receptor and ligand status in thymic carcinoma. Lung Cancer 77(3):515-521, 9/2012. e-Pub 6/20/2012. PMID: 22726920.
15. Byers LA, Wang J, Nilsson MB, Fujimoto J, Saintigny P, Yordy J, Giri U, Peyton M, Fan YH, Diao L, Masrorpour F, Shen L, Liu W, Duchemann B, Tumula P, Bhardwaj V, Welsh J, Weber S, Glisson BS, Kalhor N, Wistuba II, Girard L, Lippman SM, Mills GB, Coombes KR, Weinstein JN, Minna JD, Heymach JV. Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1. Cancer Discov 2(9):798-811, 9/2012. e-Pub 9/6/2012. PMCID: PMC3567922.
16. Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJ. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol 6(12):2104-11, 12/2011. e-Pub 9/2011. PMID: 21892101.
17. Tang X, Kadara H, Behrens C, Liu DD, Xiao Y, Rice D, Gazdar AF, Fujimoto J, Moran C, Varella-Garcia M, Lee JJ, Hong WK, Wistuba II. Abnormalities of the TITF-1 lineage-specific oncogene in NSCLC: Implications in lung cancer pathogenesis and prognosis. Clin Cancer Res 17(8):2434-43, 4/15/2011. e-Pub 1/21/2011. PMCID: PMC3078948.
18. Chen Y, Deng J, Fujimoto J, Kadara H, Men T, Lotan D, Lotan R. Gprc5a deletion enhances the transformed phenotype in normal and malignant lung epithelial cells by eliciting persistent Stat3 signaling induced by autocrine Lif. Cancer Res 70(21):8917-8926, 11/1/2010. e-Pub 10/19/2010. PMCID: PMC2970717.
19. Fujimoto J, Kong M, Lee JJ, Hong WK, Lotan R. Validation of a Novel Statistical Model for Assessing the Synergy of Combined-agent Cancer Chemoprevention. Cancer Prev Res (Phila Pa) (*Cover of Cancer Prev Res) 3(8):917-928, 07/27/2010, 7/2010. e-Pub 7/2010. PMID: 20663979.
20. Kadara H, Fujimoto J, Men T, Ye X, Lotan D, Lee JS, Lotan R. A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent and associated with survival in human lung adenocarcinomas. Neoplasia 12(6):499-505, 6/2010. e-Pub 6/2010. PMCID: PMC2887090.
21. Deng J*, Fujimoto J*(*co-first authors), Ye XF, Men TT, Van Pelt CS, Chen YL, Lin XF, Kadara H, Tao Q, Lotan D, Lotan R. Knockout of the Tumor Suppressor Gene Gprc5a in Mice Leads to NF-{kappa}B Activation in Airway Epithelium and Promotes Lung Inflammation and Tumorigenesis. Cancer Prev Res (Phila Pa) (*Commentary in the same issue of Cancer Prev Res) 3(4):424-37, 4/2010. e-Pub 3/2010. PMID: 20354164.
22. Fujimoto J, Kadara H, Men T, van Pelt C, Lotan D, Lotan R. Comparative Functional Genomics Analysis of NNK Tobacco-Carcinogen Induced Lung Adenocarcinoma Development in Gprc5a-Knockout Mice. PLoS One 5(7):e11847, 2010. PMID: 20686609.
23. Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM, Huang J, Spinola M, Dong W, Yin G, Fujimoto J, Kim E, Xie Y, Girard L, Moran C, Hong WK, Minna JD, Wistuba II. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One 5(2):e9112, 2010. PMCID: PMC2817751.
24. Tao Q, Fujimoto J, Men T, Ye X, Deng J, Lacroix L, Clifford JL, Mao L, Van Pelt CS, Lee JJ, Lotan D, Lotan R. Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst (*Commentary in the same issue of J Natl Cancer Inst) 99(22). e-Pub 11/2007. PMID: 18000218.
25. Tahara M, Ochiai A, Fujimoto J, Boku N, Yasui W, Ohtsu A, Tahara E, Yoshida S. Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil. Oncol Rep 11(1):9-15, 1/2004. PMID: 14654896.
26. Fujimoto J, Yasui W, Tahara H, Tahara E, Kudo Y, Yokozaki H, Tahara E. DNA hypermethylation at the pS2 promoter region is associated with early stage of stomach carcinogenesis. Cancer Lett 149(1-2):125-34, 2/2000. PMID: 10737716.
27. Yasui W, Yokozaki H, Fujimoto J, Naka K, Kuniyasu H, Tahara E. Genetic and epigenetic alterations in multistep carcinogenesis of the stomach. J Gastroenterol 35 Suppl 12:111-5, 2000. PMID: 10779229.
28. Yokozaki H, Shitara Y, Fujimoto J, Hiyama T, Yasui W, Tahara E. Alterations of p73 preferentially occur in gastric adenocarcinomas with foveolar epithelial phenotype. Int J Cancer 83(2):192-6, 10/1999. PMID: 10471526.
29. Yasui W, Naka K, Suzuki T, Fujimoto J, Hayashi K, Matsutani N, Yokozaki H, Tahara E. Expression of p27Kip1, cyclin E and E2F-1 in primary and metastatic tumors of gastric carcinoma. Oncol Rep 6(5):983-7, Sep-Oct, 9/1999. PMID: 10425291.
30. Yasui W, Fujimoto J, Suzuki T, Ono S, Naka K, Yokozaki H, Tahara E. Expression of cell-cycle-regulating transcription factor E2F-1 in colorectal carcinomas. Pathobiology 67(4):174-9, Jul-Aug, 7/1999. PMID: 10738178.
31. Yasui W, Tahara E, Tahara H, Fujimoto J, Naka K, Nakayama J, Ishikawa F, Ide T, Tahara E. Immunohistochemical detection of human telomerase reverse transcriptase in normal mucosa and precancerous lesions of the stomach. Jpn J Cancer Res 90(6):589-95, 6/1999. PMID: 10429648.
32. Tahara H, Yasui W, Tahara E, Fujimoto J, Ito K, Tamai K, Nakayama J, Ishikawa F, Tahara E, Ide T. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene 18(8):1561-7, 2/25/1999. PMID: 10102626.
33. Yokozaki H, Semba S, Fujimoto JY, Tahara E. Microsatellite instabilities in gastric cancer patients with multiple primary cancers. Int J Oncol 14(1):151-5, 1/1999. PMID: 9863022.
34. Yasui W, Tahara H, Tahara E, Fujimoto J, Nakayama J, Ishikawa F, Ide T, Tahara E. Expression of telomerase catalytic component, telomerase reverse transcriptase, in human gastric carcinomas. Jpn J Cancer Res 89(11):1099-103, 11/1998. PMID: 9914776.
35. Yasui W, Kudo Y, Naka K, Fujimoto J, Ue T, Yokozaki H, Tahara E. Expression of CD44 containing variant exon 9 (CD44v9) in gastric adenomas and adenocarcinomas: relation to the proliferation and progression. Int J Oncol 12(6):1253-8, 6/1998. PMID: 9592182.

Invited Articles

1. Fujimoto J, Wistuba II. Current concepts on the molecular pathology of non-small cell lung cancercarcinoma. Semin Diagn Pathol 31(4):306-13, 7/2014. e-Pub 6/12/2014. PMCID: PMC4190584.
2. Fujimoto J, Wistuba II. Updated Comprehensive Cancer Research Project in United States. -Challenges at University of Texas M.D. Anderson Cancer Center Thoracic Molecular Pathology Lab-. Nihon Rinsho (Japanese), 11/2013.
Other Articles
1. Katayama N, Yamamoto M, Ihara A, Fujimoto J, Kanazawa S. A case of idiopathic thorombocytopenic purpura treated by splenic irradiation. Journal of JASTRO (Japanese Society for Therapeutic Radiology and Oncology) 17(1):35-39, 3/2005.
2. Ishida K, Taniyama K, Toda T, Fujimoto K, Murakami K, Motoshita J, Fujimoto J. A very fast cell transfer method using a microwave with special references to several stainings and FISH. Journal of the Japanese Society of Clinical Cytology 44(6):353-359, 2005.
3. Nishi Y, Shirane M, Date T, Nishiura T, Fujimoto J. Case of NK/T-cell lymphoma of the larynx with hemophagocytic syndrome. Nippon Jibiinkoka Gakkai Kaiho 107(10):966-969, 10/2004. PMID: 15559300.
4. Kaneko S, Madokoro N, Nakano K, Muramkami K, Fujimoto J, Taniyama K. An Autopsy Case of Dermatomyositis with Severe Dysphagia. Nishinihon Journal of Dermatology 66(3):232-235, 2004.

Abstracts

1. Zhang J, Fujimoto J, Zhang J, Cao Y, Chow C, Gold KA, Gumbs C, Heymach J, Kalhor N, Moran C, Protopopov A, Seth S, Song X, Swisher S, Tang J, William WN, Wu X, Hong WK, Wistuba II, Futreal A. Intratumor heterogeneity (ITH) of lung adenocarcinomas defined by multiregion whole exome sequencing (WES). 2014 ASCO Annual Meeting. e-Pub 6/2014.
2. Aisner D, Sholl LM, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, Heidi Chen H, Fujimoto J, Kugler K, Franklin WA, Johnson BE, Minna JD, Kris MG, Bunn PA, Kwiatkowski DJ. Multi-institutional multiplexed genetic analysis in lung adenocarcinoma: The Lung Cancer Mutation Consortium (LCMC I) experience. 2014 ASCO Annual Meeting. e-Pub 6/2014.
3. Fujimoto J, Hori T, Weissferdt A, Kalhor N, Fukuoka J, Wistuba II, Moran C. Histopathological evaluation of thymic epithelial tumors using spiral array technology. The 103rd Annual Meeting of the Japanese Society of Pathology, 4/2014.
4. Kusko R, Anderlind C, Wang G, Zhang S, Wallace D, Walser T, Ebright M, Garcia MM, Eisenberg R, Lee G, Liu G, Elashoff D, Kalhor N, Moran C, Mehran R, Fujimoto J, Massion PP, Dubinett S, Wistuba II, Lenburg M, Kadara H, Spira A. Mapping the airway-wide molecular field of injury in smokers with lung cancer. Annual Meeting American Association for Cancer Research, 2014. e-Pub 4/2014.
5. Zhang YA, Ma X, Fujimoto J, Wistuba II, Lam S, Stastny V, Gao B, Larsen J, Liu X, Minna JD, Zhang MQ, Gazdar AF. SCT methylation is a potential cancer biomarker for lung cancer. Annual Meeting American Association for Cancer Research, 2014 (#1855), 4/2014.
6. Maki Y, Fujimoto J, Yoo SY, Garcia MM, Chow CW, Chu Z, Shen L, Kalhor N, Moran CA, Wang J, Coombes KR, Wistuba II, Kadara H. The transcriptomic architecture of the field of cancerization in the adjacent normal-appearing airway comprises early mechanisms in lung carcinogenesis. Annual Meeting American Association for Cancer Research, 2014, 4/2014.
7. Fujimoto J, Zhang J, Pickering CR, Kadara H, Liu CG,Drummond JA, Muzny DM, Doddapaneni HV, Weissferdt A, Wheeler DA, Myers JN, Wang J, Wistuba II, Kalhor N, Moran C. Identification of Novel Somatic Variants in Thymic Epithelial Tumors by Next-Generation Sequencing. 103rd United States & Canadian Academy of Pathology annual meeting, 3/2014.
8. Fujimoto J, Kadara H, Wistuba II. Challenges to Investigate Lung Carcinogenesis at the University of Texas M.D. Anderson Cancer Center Thoracic Molecular Pathology Lab. 18th Congress of the Asian Pacific Society of Respirology, 11/2013.
9. Fujimoto J, Wistuba II. Challenges Personalized Medicine at MD Anderson Cancer Center Thoracic Molecular Pathology Lab. The 51st Annual Meeting of Japan Society of Clinical Oncology, 10/2013.
10. Zhang YA, Ma X, Fujimoto J, Wistuba I, Lam S, Stastny V, Gao B, Larsen J, Liu X, Minna JD, Zhang MQ, Gazdar AF. SCT methylation is a highly sensitive and specific biomarker for lung cancer. the Canary Foundation Early Detection Symposium, 10/2013.
11. Gold KA, Byers LA, Fan YH, Fujimoto J, Tse W, Lee JJ, Gupta S, Wistuba II, Stewart DJ, Gibbons DL. A Phase I/II Trial Combining Erlotinib (E) with Gamma Secretase Inhibitor RO4929097 (R) in Advanced Non-Small Cell Lung Cancer (NSCLC). 2013 ASCO Annual Meeting, 6/2013.
12. Kilari D, Tang X, Chow CW, Fujimoto J, Kalhor N, Swisher S, Wistuba II, Stewart DJ, Siddik ZH, Kim ES. Copper transporter CTR1 expression and tissue platinum concentration in NSCLC. 2013 ASCO Annual Meeting, 6/2013.
13. Maki Y, Fujimoto J, Yoo SY, Gower A, Kabbout M, Shen L, Garcia MG, Chow CW, Hong WK, Kalhor N, Wang J, Moran CA, Spira A, Coombes KR, Wistuba II, Kadara H. Transcriptomic architecture of the airway field cancerization in early-stage non-small cell lung cancer. The 104th Annual Meeting American Association for Cancer Research, 2013, 4/2013.
14. Kalhor N, Fujimoto J, Rodriguez J, Byers LA, Kies MS, Hofstetter WL, El-Naggar AK, Bell D. MECT1-MAML2 Fusion Transcript Expression in Lung Mucoepidermoid Carcinoma. The 102nd USCAP Annual Meeting 2013, 3/2013.
15. Fujimoto J, Suraokar M, Fukuoka J, Aoe K, Kadara H, Behrens C, Hori T, Fujimoto N, Kishimoto T, Inai K, Hiroshima K, Mehran R, Tsao A, Wistuba II. The University of Texas MD Anderson Cancer Center Mesothelioma Program. The 53rd Annual Meeting of the Japan Lung Cancer Society, 2012, 11/2012.
16. Fukuoka J, Hori T, Fujimoto J. Make of Tissue Bank Using Various Tissue Microarray Methods. The 38th Annual National Society for Histotechnology Symposium, 2012, 10/2012.
17. Behrens C, Lombardi F, Wagner S, Fujimoto J, Raso MG, Spaggiari L, Galetta D, Huges E, Reid JE, Sangale Z, Swisher S, Kalhor N, Moran C, Gutin A, Lanchbury JS, Kim ES, Barberis M, Wistuba II. A proliferation-based mRNA signature predicts outcome in early stage non-small cell lung adenocarcinoma. 2012 ASCO Annual Meeting, 6/2012.
18. Tsao AS, Harun N, Fujimoto J, Devito V, Lee JJ, Mehran RJ, Hong WK, Suraokar MB, Wistuba II. Elevated PDGFRB gene copy number gain is prognostic in resected malignant pleural mesothelioma. 2012 ASCO Annual Meeting, 6/2012.
19. Fujimoto J, Kadara H, Fukuoka J, Aoe K, Fujimoto N, Kishimoto T, Inai K, Hiroshima K, Suraokar MB, Mehran RJ, Tsao AS, Wistuba II. Expression patterns of the G protein-coupled receptor, GPRC5A, in human malignant pleural mesothelioma. The 101st Annual Meeting of the Japanese Society of Pathology, 4/2012.
20. Fujimoto J, Kadara H, Fukuoka J, Aoe K, Fujimoto N, Kishimoto T, Inai K, Hiroshima K, Suraokar M, Tsao AS, Mehran R. Expression patterns of the G protein-coupled receptor, GPRC5A, in human malignant pleural mesothelioma. The 103rd Annual Meeting American Association for Cancer Research, 2012, 4/2012.
21. Galindo HG, Sollis LM, Fujimoto J, Hanson N, McDowell C, Riquelume E, Tang XM, Behrens C, Lee JJ, Kim ES, Wistuba II, Erickson H. FFPE DNA Recovery for High-throughput Genotyping of NSCLC Tissues. The 103rd Annual Meeting American Association for Cancer Research, 2012, 4/2012.
22. Fujimoto J, Kadara H, Woo SK, Melinda Garcia M, Kabbout M, Basey A, Wang J, Coombes KR, Kim ES, Hong WK, Kalhor N, Moran C, Wistuba II. Gene expression profiling of lung field cancerization reveals potential targets for chemoprevention. The 101st Annual Meeting of the Japanese Society of Pathology, 4/2012.
23. Kadara H, Fujimoto J, Woo SY, Garcia M, Kabbout M, Basey A, Wang J, Coombes KR, Kim ES, Hong WK, Kalhor N, Moran C, Wistuba II. Gene expression profiling of lung tumors and matched normal airways reveals common and disparate aberrant pathways in squamous cell carcinoma and adenocarcinoma development and potential markers for detection and targets for chemoprevention in early stage lung cancer. The 103rd Annual Meeting American Association for Cancer Research, 2012, 4/2012.
24. Kabbout M, Garcia M, Fujimoto J, Chow CW, Woods D, Koch P, Solis LM, Behrens C, Wistuba II, Kadara H. Tumor suppressor effects of ETS2 transcriptional factor in human non-small cell lung cancer pathogenesis. The 103rd Annual Meeting American Association for Cancer Research, 2012, 4/2012.
25. Galindo H, Solis LM, Hanson NE, McDowell C, Fujimoto J , Riquelme E, Tang XM, Behrens C, Lee JJ, Kim ES, Wistuba II, Erickson HS. High-throughput Mutation Analysis of Formalin Fixed Paraffin-Embedded (FFPE) Non-small Cell Lung Cancer Tissues. The 12th Annual Targeted Therapies of the Treatment of Lung Cancer, 2012, 2/2012.
26. Suraokar M, Zhang Y, Chow CW, Kim D, Diao L, Fujimoto J, Mehran R, Wang J, Behrens C, Coombes K, Tsao AS, Wistuba II. Investigating the potential of miR-203 as a therapeutic candidate and its role in the pathobiology of malignant pleural mesothelioma (MPM). AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy, and Personalized Medicine, 1/2012.
27. Kim ES, Chow CW, Kalhor N, Fujimoto J, Swisher SG, Wistuba II, Stewart DJ, Siddik Z. Effects of Tissue Platinum Concentration on Tumor Response in Non-small Cell Lung Cancer. The 14th World Conference on Lung Cancer 6(6):S400-401, 7/2011.
28. Byers LA, Nilsson M, Fujimoto J, Santigny P, Wang J, Diao L, Peyton M, Fan Y-H, Giri U, Weber S, Duchemann B, Girard L, Coombes K, Weinstein J, Minna JD, Wistuba I, Heymach JV. Investigation of PARP1 as a novel therapeutic target in small cell lung cancer. The 14th World Conference on Lung Cancer 6(6):S1530-1531, 7/2011.
29. Papadimitrakopoulou V, Liu S, Fujimoto J, Wistuba I, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Kies M, Hong WK, Stewart DJ, Tsao A. Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer. The 14th World Conference on Lung Cancer 6(6):S1235, 7/2011.
30. Behrens C, Ping Y, Solis LM, Saintigny P, Kadara H, Fujimoto J, Moran CA, Swisher S, Heymach JV, Wistuba II. EZH2 expression is an early event in the pathogenesis of non-small cell lung cancer (NSCLC) and correlates with tumor progression. The 102nd Annual Meeting American Association for Cancer Research, 2011 52:764-765, 4/2011.
31. Galindo HG, Suraokar M, Behrens C, Woods D, Kalhor N, Sldape K, Fujimoto J, Herbst R Erickson H, Wistuba II. Identification of Prostate Stem Cell Antigen (PSCA) as a Potential Marker for Lung Cancer Brain Metastasis. The 102nd Annual Meeting American Association for Cancer Research, 2011 52:1238-1239, 4/2011.
32. Fujimoto J, Kadara HN, Behrens C, Liu D, Lee JJ, Solis LM, Kim ES, Shalafkhane A, Wistuba II, Lotan R. Implication of GPRC5A loss in lung carcinogenesis in patients with and without chronic obstructive pulmonary disease. The102nd Annual Meeting American Association for Cancer Research, 2011 52:527, 4/2011.
33. Solis LM, Raso MG, Fujimoto J, Behrens C, Woods D, Mendoza G, Kalhor N, Moran CA, Wistuba II. Molecular abnormalities associated to the progression of lung adenocarcinomas with BAC features from non-invasive to invasive patterns. The 102nd Annual Meeting American Association for Cancer Research, 2011 52:340, 4/2011.
34. Fujimoto J, Kadara HN, Behrens C, Liu D, Lee JJ, Fukuoka J, Solis LM, Kim ES, Shalafkhane A, Wistuba II, Lotan R. The G-protein coupled receptor family C group 5 member A loss is implicated in lung carcinogenesis. The 100th Annual meeting of the Japanese Society of Pathology, 4/2011.
35. Fujimoto J, Wang H, Lotan D, Lotan R. In vitro and in vivo expression of GPRC5A in pancreatic cancer. The 6th International Society of Gastroenterological Carcinogenesis (#5), 1/2011.
36. Kong M, Lee JJ, Fujimoto J, Lotan R. Nonparametric Methods for Evaluating Drug Activity and Synergy for Three Drug Combinations. The 33rd Annual Midwest Biopharmacetical Statistics Workshop, 5/2010.
37. Chen Y, Deng J, Fujimoto J, Kadara H, Ye X, Men T, Lotan D, Lotan R. Loss of the lung-specific tumor suppressor Gprc5a causes persistent activation of Stat3 leading to increased survival signaling in normal and malignant lung epithelial cells. The 101st Annual Meeting American Association for Cancer Research, 2010 51:1213, 4/2010.
38. Fujimoto J, Kadara HN, Tao Q, Men T, Van Pelt C, Lotan D,Lotan R. Relevance of tobacco carcinogen-enhanced lung tumorigenesis in Gprc5a-KO mice to human lung cancer. The 99th Annual meeting of the Japanese Society of Pathology, 4/2010.
39. Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM, Huang J, Spinola M, Dong W, Yin G, Fujimoto J, Kim E, Xie Y, Girard L, Moran C, Hong WK, Minna JD, Wistuba II. Sex determining region Y-box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. The 101st Annual Meeting American Association for Cancer Research, 2010 51:1253, 4/2010.
40. Fujimoto J, Kadara HN, Tao Q, Men T, van Pelt C, Lotan D, Lotan R. Tobacco carcinogen-enhanced lung tumorigenesis in Gprc5a knockout mice recapitulates human lung cancer development. The 101st Annual Meeting American Association for Cancer Research, 2010 51:598, 4/2010.
41. Fujimoto J, Kadara HN, Men TT, Lotan R. Enhanced tobacco carcinogen-induced lung tumorigenesis in tumor suppressor Gprc5a knockout mice and its relation to human lung cancer prognosis. The 98th Annual meeting of the Japanese Society of Pathology, 4/2009.
42. Kadara HN, Fujimoto J, Men TT, Lotan D, Ye X, Lee JS, Lotan R. Gene expression signatures of tumor suppressor Gprc5a loss in murine lung cells predict poor survival in human lung adenocarcinomas. The 100th Annual Meeting American Association for Cancer Research, 2009, 4/2009.
43. Deng J, Fujimoto J, Ye X, Men TT, Lin X, Chen Y, Lotan D, Lotan R. The lung tumor suppressor GPRC5A inhibits activation of NF-kB in human non-small cell lung adenocarcinoma cells. The 100th Annual Meeting American Association for Cancer Research, 2009, 4/2009.
44. Fujimoto J, Men TT, Van Pelt CS, Lotan R. Loss of the lung-specific tumor suppressor Gprc5a sensitizes knockout mice to NNK-induced lung carcinogenesis. American Association for Cancer Research Special Conference in Cancer Research Mouse Models of Cancer, 1/2009.
45. Fujimoto J, Men TT, Van Pelt CS, Lee JJ, Gu X, Kopelovich L, Lotan R. Chemoprevention of NNK-induced lung carcinogenesis in the Gprc5a knockout mouse by budesonide. The 99th Annual Meeting American Association for Cancer Research, 2008, 4/2008.
46. Deng J, Ye X, Fujimoto J, Tao Q, Men TT, Van Pelt CS, Lin X, Chen Y, Lotan D, Lotan R. The 99th Evidence for the involvement of NF-{kappa}B and inflammation in the promotion of lung carcinogenesis in the Gprc5a knockout mouse model. The 99th Annual Meeting American Association for Cancer Research, 2008, 4/2008.
47. Fujimoto J, Men TT, Lee JJ, Newman RA, Kopelovich L, Lotan R. Effects of the synthetic retinoid fenretinide on lung carcinogenesis in Gprc5a knockout mice exposed to the tobacco carcinogen NNK. The Symposium in honor of Dr. Levin, Colorectal Cancer: Celebrating a Career in Cancer Prevention, 6/2007.
48. Fujimoto J, Men TT, Lee JJ, Newman RA, Kopelovich L, Lotan R. Effects of the synthetic retinoid fenretinide on lung carcinogenesis in Gprc5a knockout mice exposed to the tobacco carcinogen NNK. The 98th Annual Meeting American Association for Cancer Research, 2007, 4/2007.
49. Lotan R, Men TT, Fujimoto J, Ye X, Deng J, Lacroix L, Mao L, Van Pelt C, Tao Q. GPCR5A knockout mouse: A new model for lung carcinogenesis. Fifth AACR International Conference on Frontiers in Cancer Prevention Research, 11/2006.
50. Jun KH, Fujimoto J, Lotan R. Enhancement of apoptosis induction by the synthetic retinoid MX3350-1 in non-small cell lung cancer cells by p53-dependent pathway. The 97th Annual Meeting American Association for Cancer Research, 4/2006.
51. Fujimoto J, Hong WK, Lotan R. Antineoplastic action of 5-aza-2'-deoxycytidine and suberoylanilide hydroxamic acid (SAHA) on human lung carcinoma cells. The 96th Annual Meeting American Association for Cancer Research, 4/2005.

Book Chapters

1. Tahara E., Fujimoto J, Yasui W, Yokozaki H. Dysplasia in the stomach. In: The Proceeding of the 2nd International Congress on Gastroenterological Carcinogenesis. Monduzzi Editore: Ulm, Germany, 229-233, 1999.
2. Tahara E, Yokozaki H, Fujimoto J, Shimamoto F, Yasui W. Molecular mechanisms of gastric cancer and molecular diagnosis. In: The Proceeding of 3rd International Gastric Cancer Congress. Monduzzi Editore: Seoul, Korea, 97-102, 1999.
3. Tahara E, Yasui W, Fujimoto J, Yokozaki H. Genetic and epigenetic alterations in gastric cancer: Application to molecular diagnosis. In: The Proceeding of the 17th International Cancer Congress. Monduzzi Editore: Rio de Janeiro, Brazil, 919-923, 1998.

Grant & Contract Support

Title: Clinically Actionable Mutation Profiling for Cancer Personalized Medicine Using Scalable Ultra Deep Next Gen Sequencing
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Pathologist
Principal Investigator: Ignacio Wistuba
Duration: 6/30/2012 - 5/31/2015
 
Title: Detection of Early Lung Cancer Among Military Personnel (DECAMP)
Funding Source: DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP)
Role: Pathologist
Principal Investigator: Avrum Spira
Duration: 9/30/2011 - 9/29/2016

Last updated: 10/27/2014